Today: 22 November 2025
Subscribe
Browse Category

Pharmaceuticals News 18 November 2025 - 21 November 2025

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO) is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1 Today’s trading comes against a flurry of fresh news: Below is
21 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend yield. Pfizer stock price on November 21, 2025 Pfizer (NYSE: PFE) staged a solid rebound in Friday’s regular session: For context, Pfizer’s shares are still down about 8% year-to-date, even as the broader large-cap pharma peer group has gained more than 15%, according to new Zacks analysis. Nasdaq That combination — a beaten-down share price, a high yield and fresh
21 November 2025
 ·  ·  ·  ·  · 
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related disease, released a new press release highlighting fresh in‑vitro data in human leukemia cells. FinanzNachrichten.de+1 In parallel, investors digested a separate corporate governance update: the company disclosed that board member Dr. Craig Eagle has stepped down, effective November 14, 2025,
21 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer stock (NYSE: PFE) spent most of Thursday in the red as investors weighed a near‑7% dividend yield against fresh legal headlines, new R&D wins and ongoing questions about the company’s post‑COVID growth story. As of late U.S. trading on November 20, 2025, Pfizer shares were changing hands around $24.45, down roughly 1.7% on the day, with heavy volume of more than 44 million shares. Below is a deep dive into what’s moving PFE today—and what it could mean for the stock in the weeks ahead. Pfizer Share Price on November 20, 2025 A German market recap noted that despite
20 November 2025
 ·  ·  ·  ·  · 
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after unveiling a trio of significant updates on November 20, 2025: The moves come as Moderna tries to navigate a steep post‑pandemic revenue reset, heavy R&D spending and investor skepticism about how quickly its broad mRNA pipeline can translate into sustainable
20 November 2025
 ·  ·  ·  ·  · 
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of 50 kg of high‑potency iboga bark that is now being processed into ibogaine HCl and full‑spectrum Total Alkaloid Extracts for global clinical and therapeutic markets. GlobeNewswire+1 At the same time, Psyence BioMed’s stock was flagged by Benzinga among Thursday’s top
20 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday, November 20, 2025, Novo Nordisk’s U.S.-listed ADR (ticker NVO) is trading around $49, roughly in line with Wednesday’s close, after a 3% rebound the previous day. StockInvest+1 In Copenhagen, Novo Nordisk’s Class B shares are last quoted around DKK 318–319, up roughly 2–2.5% on the session, according to data from Investing.com and TradingView. Investing.com+2Investing.com+2 At the same time, the company
20 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts

Updated: November 19, 2025 Rani Therapeutics Holdings (NASDAQ: RANI) finished Wednesday, Nov. 19, 2025 at $1.75, down from $1.86 on Tuesday. The stock opened at $1.83, traded between $1.70–$1.90, and moved ~2.5M shares on the day, according to end‑of‑day pricing data. Yahoo Finance Today’s trading at a glance (19.11.2025) Was there fresh company news today?As of publication on Nov. 19, no new Rani press releases or material company updates were posted today. The most recent company news remains the Q3 2025 results issued Nov. 6. Rani Therapeutics, LLCLikewise, no new SEC filings were posted today; the latest notable filing was
20 November 2025
 ·  ·  ·  ·  · 
Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is in the spotlight today after unveiling topline results from its pivotal Phase 3 RISE UP trial of mitapivat (Pyrukynd) in sickle cell disease (SCD) — data that are being widely described as “mixed” and have sent the stock sharply lower. GlobeNewswire+2Reuters+2 The study hit one of its two primary endpoints and showed strong effects on markers of hemolysis, but it failed to significantly reduce painful sickle cell crises or fatigue across the full study population — the outcomes many investors were most focused on. GlobeNewswire+2Reuters+2 Key Takeaways From Today’s Agios (AGIO) News What Agios
19 November 2025
 ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

At a glance — price & drivers (midday, Nov. 18, 2025) Market action and context KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the stock. Reuters Overnight and early‑morning coverage underscored the legal pressure, noting KVUE fell as the court weighed revival of the suits—sentiment that carried into today’s trading. Bloomberg Law Dividend: payout still on track for Nov. 26 In a separate Texas
18 November 2025
 ·  ·  ·  ·  ·  · 
Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (NASDAQ: ARVN) jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. ARVN stock pops on November 18, 2025 Arvinas shares are in rally mode this Tuesday. By mid‑afternoon U.S. trading, ARVN is up more than 14% on the day, with intraday prices hovering around the low‑$13 level and turnover far above normal. Quiver Quantitative+1 Pre‑market data set the tone: ChartMill flagged Arvinas as one of the most active names before the bell, with premarket quotes around $13.60, up more than 23% from the
18 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk (NYSE: NVO) remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its ConvaTec stake in London. U.S.-listed shares were modestly lower intraday as investors weighed near‑term pricing pressure against potential volume gains and ongoing governance/pipeline developments. Reuters+2NovoCare+2 Live price snapshot (U.S. ADS: NVO) As of 16:12:38 UTC on Nov 18, 2025, NVO traded at $47.55, down 1.9% on the day (intraday range: $47.27–$48.03). Volumes were ~7.9 million shares. Note: U.S. market moves
18 November 2025
 ·  ·  ·  ·  · 
1 2 3 … 10
Go toTop